Chemotherapy Rechallenge or Reintroduction Compared to Regorafenib or Trifluridine/Tipiracil for Pretreated Metastatic Colorectal Cancer Patients: A Propensity Score Analysis of Treatment Beyond Second Line (Proserpyna Study)
-
Published:2024-06
Issue:
Volume:
Page:
-
ISSN:1533-0028
-
Container-title:Clinical Colorectal Cancer
-
language:en
-
Short-container-title:Clinical Colorectal Cancer
Author:
Calegari M.A.ORCID,
Zurlo I.V.,
Dell'Aquila E.,
Basso M.,
Orlandi A.,
Bensi M.,
Camarda F.,
Anghelone A.,
Pozzo C.,
Sperduti I.,
Salvatore L.,
Santini D.,
Corsi D.C.,
Bria E.,
Tortora G.
Reference33 articles.
1. Pan-Asian adapted ESMO consensus guidelines for the management of patients with metastatic colorectal cancer: a JSMO-ESMO initiative endorsed by CSCO, KACO, MOS, SSO and TOS;Yoshino;Ann Oncol,2018
2. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial;Grothey;Lancet,2013
3. Randomized trial of TAS-102 for refractory metastatic colorectal cancer;Mayer;N Engl J Med,2015
4. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial;Li;Lancet Oncol,2015
5. Effect of fruquintinib vs placebo on overall survival in patients with previously treated metastatic colorectal cancer: the FRESCO randomized clinical trial;Li;JAMA,2018